Imaging Technology

JULY 28, 2023

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H. Recently approved by the U.S.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

AuntMinnie

JANUARY 30, 2024

Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. In 2018, Alosco received nearly $800,000 from the National Institutes of Health's National Institute of Neurological Disorders and Stroke for the research.

MRI 105

MRI Radiopharmaceuticals Disease Imaging 105

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group. 18F-rhPSMA-7.3

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98